Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (PILGRIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01054105
Recruitment Status : Completed
First Posted : January 22, 2010
Last Update Posted : December 27, 2018
Sponsor:
Collaborators:
Seoul National University Hospital
Seoul National University Bundang Hospital
The Catholic University of Korea
Bayer
Information provided by (Responsible Party):
Wook-Jin Chung, Gachon University Gil Medical Center

Brief Summary:
In the present study, the investigators want to investigate the prevalence of BMPR-2 gene mutations in the Korean PAH patients (Step-I) and to test that the PAH patients treated with iloprost inhalation solution (Ventavis®) would show hemodynamic response, especially assessed by exercise echocardiography (Step-II).

Condition or disease Intervention/treatment
Pulmonary Arterial Hypertension Drug: Iloprost

Detailed Description:

Pulmonary arterial hypertension (PAH) consists of a group of vascular abnormalities with elevated pulmonary arterial pressure and pulmonary vascular resistance. Idiopathic or familial PAH is progressive over several years and believed to be fatal without treatment. (1-2) The results of the Endothelin Antagonist tRial in mildly symptomatic PAH (EARLY) indicate that early diagnosis and treatment of PAH might improve time to clinical worsening and emphasize that PAH needs to be diagnosed and treated in the early stages. (3) Germline mutations of bone morphogenetic protein receptor (BMPR)-2, a member of the transforming growth factor (TGF)-β superfamily, have been found in familial and sporadic forms of idiopathic PAH,(4-6) and in appetite-suppressant PAH.(7) The BMPR-2 gene, on chromosome 2q33, has 13 exons. Exons 1-3 encode an extracellular domain, exon 4 encodes the transmembrane domain, exons 5-11 a serine/threonine kinase domain, and exons 12 and 13 a very large intracellular C-terminus of unknown function that appears to be unique to BMPR-2. (8) Mutations in familial PAH have been reported in all exons except for 5 and 13. (9) About 10-25% of sporadic cases of idiopathic PAH are thought to have BMPR-2 mutations (10) and rare cases of PAH associated with congenital heart disease, connective tissue disease and drug induced PAH were reported. (11-12) It is likely that genetic predispositions exist based on normal variations in genes that may influence the pulmonary circulation. However, the studies regarding prevalence of BMPR-2 gene mutations in Korean patients have not been performed.

In a previous study, family members of familial PAH patients showed an increased pulmonary artery systolic pressure (PASP) rise during exercise as assessed by echocardiography. (13-14) In other study, relatives of idiopathic/familial PAH patients displayed enhanced frequency of pulmonary hypertensive response during exercise and that this response is associated with mutations in the BMPR-2 gene. (15) These results suggest that asymptomatic gene carriers, in the absence of manifest pulmonary hypertension, might have enhanced PASP during exercise and more risk to develop resting pulmonary hypertension in the future compared with patients without gene mutations. Therefore, the treatment response by variable vasodilators (ex. calcium channel blockers, endothelin antagonist or prostacyclin analogues..) may be different based on the presence of BMPR-2 gene. In the present study, we want to investigate the prevalence of BMPR-2 gene mutations in the Korean PAH patients(Step-I) and to test that the PAH patients treated with iloprost inhalation solution (Ventavis®) would show hemodynamic response, especially assessed by exercise echocardiography (Step-II).

Layout table for study information
Study Type : Observational
Actual Enrollment : 73 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Prevalence of BMPR-2 Gene Mutations in Korean Patients With Pulmonary Arterial Hypertension (PAH) and the Effects of Gene Mutations on Hemodynamic Response by Drug Therapy
Study Start Date : October 2010
Actual Primary Completion Date : December 25, 2018
Actual Study Completion Date : December 25, 2018


Group/Cohort Intervention/treatment
Step I: BMPR-2 gene analysis
BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
Drug: Iloprost
Iloprost inhalation, 2.5 - 5mcg, 6 times per day
Other Names:
  • Allowable patients from Step-I
  • Step-II: Illoprost and Exercise Echo

Step-II: Iloprost and Exercise Echo
Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
Drug: Iloprost
Iloprost inhalation, 2.5 - 5mcg, 6 times per day
Other Names:
  • Allowable patients from Step-I
  • Step-II: Illoprost and Exercise Echo




Primary Outcome Measures :
  1. Cardiopulmonary exercise test parameters [ Time Frame: after 3 months active follow-up ]

Secondary Outcome Measures :
  1. Major cardiovascular Events (cardiovascular mortality, all cause mortality, hospitalization) [ Time Frame: After 2 years follow-up ]
    cardiovascular mortality, all cause mortality, hospitalization

  2. Six-minutes walking test [ Time Frame: After 3 months active follow-up ]
    min

  3. WHO/NYHA class [ Time Frame: After 3 months active follow-up ]
    WHO/NYHA class

  4. Echo parameters [ Time Frame: After 3 months active follow-up ]
    various echo parameters

  5. NT-proBNP [ Time Frame: After 3 months active follow-up ]
    NT-proBNP


Biospecimen Retention:   Samples With DNA
BMPR-2 genes


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Previously diagnosed PAH
Criteria

Inclusion Criteria:

  1. The patients aged from 20 to 80 years
  2. Newly diagnosed WHO category I PAH patients: Patients who meet the following criteria within 3 months obtained by right heart catheterization (mean PAP of more than 25 mm Hg at rest and mean pulmonary arterial wedge pressure (PCWP) or left ventricular end-diastolic pressure of 15 mm Hg or less) or echocardiography (peak PAP of more than 40mmHg and mean PAP more than 30mmHg).
  3. Previously diagnosed PAH patients who refractory to conventional treatment except iloprost inhalation solution (Ventavis): Patients meet the echo criteria (peak PAP of more than 40mmHg and mean PAP more than 30mmHg) who have been treated with PAH medications except iloprost inhalation solution (Ventavis) after diagnosed as WHO Group 1 PAH based on prior RHC data (above criteria) but refractory to them.
  4. The patients who are able to undergo low intensity exercise test (low dose bicycle or walking)

Exclusion Criteria:

  1. The patients with other left heart disease (category II in WHO classification of pulmonary hypertension); ex. Congestive HF, cardiomyopathy, significant valvular heart disease, significant arrhythmia, suspicious elevated PCWP.
  2. The patients with category III,IV and V in WHO classification of pulmonary hypertension:

    • Pulmonary hypertension with lung disease and/or hypoxemia
    • Chronic obstructive pulmonary disease
    • Interstitial lung disease
    • Sleep disorder breathing
    • Alveolar hyperventilation disorders
    • Chronic exposure to high altitude
    • Developmental abnormalities
    • Pulmonary hypertension due to chronic thrombotic and/or embolic disease
    • Thromboembolic obstruction of the proximal pulmonary arteries
    • Thromboembolic obstruction of the distal pulmonary arteries
    • Non-thrombotic pulmonary embolism (e.g. tumor or parasitic)
    • Miscellaneous disorders affecting the pulmonary vasculature
    • Patients with contraindication to Ventavis;(Hypersensitive to Ventavis, High risk of bleeding, which can be increased by use of Ventavis (e.g. active peptic ulcer, trauma, intracranial hemorrhage)
    • Severe coronary disease
    • Unstable angina
    • History of Acute myocardial infarction within 6 months
    • Uncompensated heart failure not under close medical monitoring
    • Severe arrhythmia
    • Suspected pulmonary congestion
    • Cerebrovascular disease within 3 months (e.g. transient ischemic attack, stoke)
    • Pulmonary hypertension due to venous occlusive disease, valvular defect with dysfunction of cardiac muscle, which is independent of pulmonary hypertension)
    • Pregnancy
    • Women with high probability of pregnancy
    • Breast feeding
    • Renal failure (creatinine clearance: less than 30mL/min)
  3. The patients concurrently using other pulmonary vasodilator (ex. Inhaled NO, endothelin antagonists) except PDE5 inhibitor
  4. The patients with poor echo window which is unavailable to accept the echo data
  5. The patients who cannot do any exercise
  6. The patients who changes medication administered during ventavis treatment
  7. The patients with allergic reaction to ventavis
  8. The patients with other systemic disease (ex. Leukemia, MM, Sickle cell anemia, significant liver disease)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01054105


Locations
Layout table for location information
Korea, Republic of
Soonchunhyang University Bucheon Hospital
Bucheon, Korea, Republic of
Gachon University Gil Hospital
Incheon, Korea, Republic of, 405-760
Seoul National University Bundang Hospital
Seongnam, Korea, Republic of
Catholic University Seoul Saint Mary's Hospital
Seoul, Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
Sungkyunkwan University Seoul Samsung Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Gachon University Gil Medical Center
Seoul National University Hospital
Seoul National University Bundang Hospital
The Catholic University of Korea
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Wook-Jin Chung, MD,PhD Gachon University Gil Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wook-Jin Chung, Professor, Gachon University Gil Medical Center
ClinicalTrials.gov Identifier: NCT01054105    
Other Study ID Numbers: WJC-IIT-1001
GIRBA 2278 ( Other Identifier: Gachon University Gil Hospital IRB )
First Posted: January 22, 2010    Key Record Dates
Last Update Posted: December 27, 2018
Last Verified: December 2018
Keywords provided by Wook-Jin Chung, Gachon University Gil Medical Center:
Pulmonary hypertension
genes
mutation
drug therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Primary Pulmonary Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Iloprost
Platelet Aggregation Inhibitors
Vasodilator Agents